ArticleThe Lancet regional health. Europe2025

Safety and efficacy of immunoguided prophylaxis for cytomegalovirus disease in low-risk lung transplant recipients in Spain: a multicentre, open-label, randomised, phase 3, noninferiority trial.

Aurora Páez-Vega et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.